Kaitlin Kennard

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Elise A. Chong, Rachel L. Lundberg, Matthew A. Lunning, Stefan K. Barta et autres

Abstract Background: CD19-directed CAR T-cell therapy (CAR-T) has improved outcomes and altered the treatment landscape for patients with relapsed/refractory large B-cell lymphomas (r/r LBCL). Despite these improvements, 60-70% of patients do not have long term remissions after CAR-T. CD20 x CD3 bispecific …

us (code pays fourni par la source)

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C. Coombs et autres

Introduction: Venetoclax has demonstrated consistent efficacy and manageable toxicity in patients with previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). However, evidence on venetoclax use in patients previously treated with Bruton tyrosine kinase inhibitors (BTKi) is limited. This real-world …

us, gb, ca (code pays fourni par la source)

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

Frederick Lansigan, Toby A. Eyre, Nilanjan Ghosh, Beenish S. Manzoor et autres

Background: An expansion of treatment options in CLL makes it important to understand contemporary practice and treatment effectiveness. However, real-world data are still emerging regarding outcomes among different therapeutic options. Aims: The study goal was to describe treatment patterns and clinical outcomes …

us, gb, ca (code pays fourni par la source)

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

Joanna Rhodes, Mazyar Shadman, Nicole Lamanna, Beenish S. Manzoor et autres

Background: Treatment outcomes for patients with chronic lymphocytic leukemia (CLL) have improved with the introduction of targeted agents. Prior research has shown that Black patients (pts) with CLL had shorter survival compared to White non-Hispanic pts. Here, we assess for the first …

us, de, ca, gb (code pays fourni par la source)

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, Stephen J. Schuster, Francine M. Foss, Iris Isufi et autres

Introduction: With a median overall survival (OS) measured in months, successful treatment of Richter's transformation (RT) of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) remains a major unmet medical need. While targeted agents, such as Bruton tyrosine kinase inhibitor …

us, cn (code pays fourni par la source)

Factors impacting treatment selection in treatment-naive patients with CLL: a multicenter study

James B. Rhodes, Kavita Sail, Maryam Sarraf Yazdy, Borroughs R. Hill et autres

Comparative analysis of targeted therapies in relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chaitra S. Ujjani et autres

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Anthony R. Mato, Stephen J. Schuster, Francine M. Foss, Iris Isufi et autres

Targeted agents have greatly improved outcomes for patients (pts) with chronic lymphocytic leukemia (CLL) and other B cell lymphomas; however, single agents have been limited by intolerance, resistance and depth/durability of responses. Current novel targeted agent combinations may improve depth of response, …

us, cn (code pays fourni par la source)

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION

Anthony R. Mato, Jakub Svoboda, Eline T. Luning Prak, Stephen J. Schuster et autres

Introduction: Preclinical data suggest that PD-1 mediates immune evasion in CLL, however clinical data indicate that pembrolizumab (pembro) monotherapy is ineffective in r/r CLL patients (pts) (0% ORR; Ding, BLOOD 2017). We hypothesized synergistic activity with PD-1 + PI3K blockade. Umbralisib (Umbra), …

us, Afrique du Sud (code pays fourni par la source)

PF386 HYPERTENSION IN PATIENTS TREATED WITH IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Lindsey E. Roeker, Maryam Sarraf Yazdy, L. Gashonia, Julie M. Goodfriend et autres

Background: Hypertension (HTN) is the most common grade ≥ 3 Ibrutinib (Ibr)‐associated adverse event (AE) observed in clinical trials (26%) (O’Brien, Blood 2015). Meta‐analysis of clinical trial data suggests a 2.8‐fold increased risk of HTN for patients (pts) treated with Ibr vs. …

us (code pays fourni par la source)

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT‐NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Joanna Rhodes, Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill et autres

Background: The approval of novel targeted agents (TA) has revolutionized the treatment landscape for patients (pts) with chronic lymphocytic leukemia (CLL). Guidelines suggest that treatment selection between chemo‐immunotherapy (CIT) and TA is driven by several factors including age, disease stage, patient's fitness, …

us, Afrique du Sud, in, gb, de (code pays fourni par la source)

HYPERTENSION (HTN) IN PATIENTS (PTS) TREATED WITH IBRUTINIB (IBR) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Maryam Sarraf Yazdy, Lindsey E. Roeker, L. Gashonia, Julie M. Goodfriend et autres

Introduction: HTN is the most common grade ≥ 3 Ibr-associated adverse event (AE) in trials (26%) (O'Brien, Blood 2015).Meta-analysis of trials suggests a 2.8-fold increased risk of HTN for pts treated with Ibr (Caldeira, PLOS ONE 2019).In practice, data on incidence, management, …

us (code pays fourni par la source)